Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Biotech
Health
First Opinion
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

Sarepta’s stock price plummets after an ‘erroneous’ report

  • Kate Sheridan

By Kate Sheridan Aug. 8, 2019

Reprints
Sarepta - Cambridge -AP
Kristoffer Tripplaar/Sipa via AP

It was not an executive shakeup that pummeled shares of Sarepta Therapeutics on Thursday. It was not rumors of a takeover Wall Street didn’t like.

Instead, it was a mistake.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Kate Sheridan

Kate Sheridan

Research Reporter

Kate collects and analyzes documents, data, and other information for biotech, health tech, science, and politics stories.

Tags

Canada case highlights possible long-term risks of experimental stem…
Canada case highlights possible long-term risks of experimental stem cell therapy
A baby with a disease gene or no baby…
A baby with a disease gene or no baby at all: Genetic testing of embryos creates…
Why fentanyl is deadlier than heroin, in a single…
Why fentanyl is deadlier than heroin, in a single photo
Why the world’s smallest wheelchairs are going unused
Why the world’s smallest wheelchairs are going unused
Wary of changes to Medicare Advantage, health insurers put…
Wary of changes to Medicare Advantage, health insurers put up a fight — and exaggerate the…
Strengthen science by funding living evidence synthesis
Strengthen science by funding living evidence synthesis

Recommended Stories